drugset / Trial / NCT00429416
Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation
Phase 1/2
Completed
14 enrolled
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this research study is to determine if an experimental agent, LLME can decrease the incidence and severity of Graft-Versus-Host-Disease (GVHD) following blood (hematopoietic) stem cell transplantation
Timeline
- Start
- 2004-03
- Primary completion
- 2008-12
- Completion
- 2009-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | L-leucyl-L-leucine Methyl Ester | Unknown | — | — |
| Background | 2-MERCAPTOETHANESULFONIC ACID | Small molecule | 1000 mg/m2 | — |
| Background | Cyclophosphamide | Other / unclassified | 1000 mg/m2 | — |
| Background | Cytarabine | Small molecule | 2000 mg/m2 | — |
| Background | Fludarabine | Small molecule | 30 mg/m2 | — |
| Background | Tacrolimus | Small molecule | — | — |
| Background | sargramostim | Protein / enzyme biologic | — | — |